All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy

Biodesix, Inc. (BDSX) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting an upward trend in earnings estimates over the past three months with a 7.8% increase in consensus estimates. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by improving business fundamentals and institutional investor buying pressure.